Ampio (AMPE) Gets U.S. Patent for DME Drug Optina
Tweet
Share
E-mailGet Alerts AMPE Hot Sheet
Join SI Premium – FREE
Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), has received notice of allowance of a patent from the US office of patents and trademarks for its DME drug Optina.
Ampio also received a notice of allowance of a similar patent from the Canadian Intellectual Property Office. These initial patents cover the North American territories and multiple additional patents for using Optina for the treatment of macular edema and diabetic retinopathy are pending worldwide.
Ampio also received a notice of allowance of a similar patent from the Canadian Intellectual Property Office. These initial patents cover the North American territories and multiple additional patents for using Optina for the treatment of macular edema and diabetic retinopathy are pending worldwide.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Kimbell Royalty closes $221.2M mineral rights acquisition
- Elroy Air wins $46M U.S. Army contract for cargo drone system
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
